181065-46-3
Chemical Structure
p-NH2-Bn-DOTA
- CAS No.: 181065-46-3
- Formula:C23H35N5O8
- Molecular Weight:509.55
IUPAC Name: (S)-2,2',2'',2'''-(2-(4-aminobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid
InChIKey: VEYDUAGNNSZVTN-IBGZPJMESA-N
SMILES: OC(CN(CCN(CCN(CCN(C1)CC(O)=O)CC(O)=O)CC(O)=O)[C@H]1CC2=CC=C(C=C2)N)=O
Biological Activity: p-NH2-Bn-DOTA is a DOTA-based bifunctional chelator used for antibody conjugation and radiometal labeling. p-NH2-Bn-DOTA can be conjugated to anti-GD2 antibodies for copper radiolabeling, and the conjugate retains antigen-binding capacity. p-NH2-Bn-DOTA can be conjugated to PAMAM dendrimers for subsequent radiometal complexation. p-NH2-Bn-DOTA can be conjugated to hu14.18K322A for Cu-64 radiolabeling[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
p-NH2-Bn-DOTA | 99.85% | p-NH2-Bn-DOTA is a DOTA-based bifunctional chelator used for antibody conjugation and radiometal labeling. p-NH2-Bn-DOTA can be conjugated to anti-GD2 antibodies for copper radiolabeling, and the conjugate retains antigen-binding capacity. p-NH2-Bn-DOTA can be conjugated to PAMAM dendrimers for subsequent radiometal complexation. p-NH2-Bn-DOTA can be conjugated to hu14.18K322A for Cu-64 radiolabeling. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 1.00
HY-W038001DOTA-benzene -
Similarity Score 0.89
HY-114377p-SCN-Bn-DOTA -
Similarity Score 0.89
HY-156038(S)-p-SCN-Bn-DOTA -
Similarity Score 0.88
HY-W782075p-NO2-Bn-DOTA -
Similarity Score 0.82
HY-W782080p-NH2-Bn-oxo-DO3A -
Similarity Score 0.80
HY-178221(S)-P-SCN-BN-NOTA -
Similarity Score 0.80
HY-178271P-SCN-Bn-NOTA -
Similarity Score 0.79
HY-W782083p-SCN-Bn-NOTA trihydrochloride -
Similarity Score 0.75
HY-W782081p-SCN-Bn-oxo-DO3A -
Explore the MedChemAI to find more analogs
References
- [1]. Vavere AL, et al. 64Cu-p-NH2-Bn-DOTA-hu14.18K322A, a PET radiotracer targeting neuroblastoma and melanoma. J Nucl Med. 2012 Nov;53(11):1772-8.
- [2]. Vats K, et al. Assessment of 177 Lu-labeled carboxyl-terminated polyamidoamine (PAMAM) dendrimer-RGD peptide conjugate. J Pept Sci. 2022 Feb;28(2):e3366. doi: 10.1002/psc.3366. Epub 2021 Aug 30. PMID: 34463002.
- [3]. Vavere A, et al. Chelator conjugation, Cu-64 radiolabeling, and in vitro and in vivo evaluation of hu14. 18K322A, an anti-GD2 antibody for imaging neuroblastoma and melanoma[J]. 2010.
